Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
117 hedge funds and large institutions have $702M invested in Adamas Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 33 increasing their positions, 33 reducing their positions, and 17 closing their positions.
214% more call options, than puts
Call options by funds: $8.83M | Put options by funds: $2.81M
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
79% more capital invested
Capital invested by funds: $391M → $702M (+$311M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
23% more funds holding
Funds holding: 95 → 117 (+22)
0% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$47.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$30.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$19.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.5M |
| 3 |
Millennium Management
New York
|
-$16.9M |
| 4 |
AC
Armistice Capital
New York
|
-$15.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Jane Street
New York
| – | -$261K | -12,339 | Closed |
|
|
FPF
127
FNY Partners Fund
New York
| – | -$231K | -10,913 | Closed |
|
|
NFA
128
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$171K | -8,068 | Closed |
|
129
SG Americas Securities
New York
| – | -$110K | -5,202 | Closed |
|
|
MCIA
130
Mountain Capital Investment Advisors
Westminster,
Colorado
| – | -$72K | -3,400 | Closed |
|
|
TRCT
131
Tower Research Capital (TRC)
New York
| – | -$31K | -1,483 | Closed |
|
|
CSS
132
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$28K | -1,300 | Closed |
|
|
HCM
133
Highlander Capital Management
Short Hills,
New Jersey
| – | -$21K | -1,000 | Closed |
|
ADMS Hedge Fund Activity: Q4 2017 in Review
117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2017, worth a combined $702M — up 79% from $391M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ADMS positions and 17 closed out — a net gain of 22 holders — while 33 added to existing stakes and 33 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $47.8M. The largest seller was Kerrisdale Advisers, cutting an estimated $19.1M.
- 117 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2017, up from 95 in Q3 2017.
- Funds reported $702M of Adamas Pharmaceuticals stock for Q4 2017, up 79% quarter-over-quarter.
- 39 funds opened new Adamas Pharmaceuticals positions in Q4 2017 and 17 closed out, a net change of +22 holders.
- The largest Adamas Pharmaceuticals buyer in Q4 2017 was Invesco, an estimated $47.8M added.
- The largest Adamas Pharmaceuticals seller in Q4 2017 was Kerrisdale Advisers, an estimated $19.1M sold.
Based on aggregated 13F filings for Q4 2017.